Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

Seminars in Cancer Biology

Volumn 27, Issue , 2014, Pages 62-73

  Turner, Joel G ^a   Dawson, Jana ^a   Cubitt, Christopher L ^a   Baz, Rachid ^a   Sullivan, Daniel M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

CRM1; Drug resistance; Multiple myeloma; Nuclear export; Nuclear pore complex; Topoisomerase II

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; BORTEZOMIB; CARFILZOMIB; CISPLATIN; CYSTEINE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EXPORTIN 1 INHIBITOR; FIRTECAN; IMATINIB; KOS 2464; KPT 185; KPT 185T; KPT 249; KPT 251; KPT 276; LENALIDOMIDE; LEPTOMYCIN B; MELPHALAN; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; OXALIPLATIN; RAN PROTEIN; SELINEXOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; CELL RECEPTOR; EXPORTIN 1 PROTEIN; KARYOPHERIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BINDING SITE; BLADDER CANCER; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); COLON CANCER; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; COVALENT BOND; DIFFUSION; DRUG CLASSIFICATION; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIZATION; DRUG TARGETING; FATIGUE; GASTROINTESTINAL SYMPTOM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYDROPHOBICITY; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MALAISE; MALIGNANT MESOTHELIOMA; METABOLIC INHIBITION; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RISK BENEFIT ANALYSIS; SOLID TUMOR; TESTIS CANCER; THROMBOCYTOPENIA; TRANSPORT KINETICS; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VOMITING; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; HUMANS; KARYOPHERINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904474343     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.03.001     Document Type: Review

References (119)

1. Reichelt R., Holzenburg A., Buhle E.L., Jarnik M., Engel A., Aebi U. Correlation between structure and mass distribution of the nuclear pore complex and of distinct pore complex components. J Cell Biol 1990, 110:883-894.
2. Lim R.Y., Aebi U., Fahrenkrog B. Towards reconciling structure and function in the nuclear pore complex. Histochem Cell Biol 2008, 129:105-116.
3. Cook A., Bono F., Jinek M., Conti E. Structural biology of nucleocytoplasmic transport. Annu Rev Biochem 2007, 76:647-671.
4. Monecke T., Guttler T., Neumann P., Dickmanns A., Gorlich D., Ficner R. Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP. Science 2009, 324:1087-1091.
5. Dong X., Biswas A., Chook Y.M. Structural basis for assembly and disassembly of the CRM1 nuclear export complex. Nat Struct Mol Biol 2009, 16:558-560.
6. Xu D., Grishin N.V., Chook Y.M. NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell 2012, 23:3673-3676.
7. Xu D., Farmer A., Collett G., Grishin N.V., Chook Y.M. Sequence and structural analyses of nuclear export signals in the NESdb database. Mol Biol Cell 2012, 23:3677-3693.
8. Sun Q., Carrasco Y.P., Hu Y., Guo X., Mirzaei H., Macmillan J., et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A 2013, 110:1303-1308.
9. Turner J.G., Dawson J., Sullivan D.M. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012, 83:1021-1032.
10. Hill R., Cautain B., de Pedro N., Link W. Targeting nucleocytoplasmic transport in cancer therapy. Oncotarget 2013, [Epub ahead of print].
11. Kudo N., Matsumori N., Taoka H., Fujiwara D., Schreiner E.P., Wolff B., et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A 1999, 96:9112-9117.
12. Meissner T., Krause E., Vinkemeier U. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms. FEBS Lett 2004, 576:27-30.
13. Shacham S., Nir R., Daelemans D., Shechter S., Vancurova I., Juvekar A., et al. KPT0127, a novel, potent and selective inhibitor of Crm1-mediated nuclear export shows selective cytoxicity for neoplastic over normal cells and is well tolerated in animals. Clin Can Res 2010, 16:A19. [abstract].
14. Sakakibara K., Saito N., Sato T., Suzuki A., Hasegawa Y., Friedman J.M., et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011, 118:3922-3931.
15. Turner J.G., Dawson J., Emmons M.F., Cubitt C.L., Kauffman M., Shacham S., et al. CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo. J Cancer 2013, 4:614-625.
16. Turner J.G., Engel R., Derderian J.A., Jove R., Sullivan D.M. Human topoisomerase IIalpha nuclear export is mediated by two CRM-1-dependent nuclear export signals. J Cell Sci 2004, 117:3061-3071.
17. Turner J.G., Dawson J., Sullivan D.M. Targeting the nuclear export signal in multiple myeloma. Blood 2013, 122:1925. [abstract].
18. Vogt P.K., Jiang H., Aoki M. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 2005, 4:908-913.
19. Craig E., Zhang Z.K., Davies K.P., Kalpana G.V. A masked NES in INI1/hSNF5 mediates hCRM1-dependent nuclear export: implications for tumorigenesis. EMBO J 2002, 21:31-42.
20. Powell S.M., Zilz N., Beazer-Barclay Y., Bryan T.M., Hamilton S.R., Thibodeau S.N., et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992, 359:235-237.
21. Pichler A., Melchior F. Ubiquitin-related modifier SUMO1 and nucleocytoplasmic transport. Traffic 2002, 3:381-387.
22. Kutay U., Guttinger S. Leucine-rich nuclear-export signals: born to be weak. Trends Cell Biol 2005, 15:121-124.
23. Yoneda Y., Hieda M., Nagoshi E., Miyamoto Y. Nucleocytoplasmic protein transport and recycling of Ran. Cell Struct Funct 1999, 24:425-433.
24. Poon I.K., Jans D.A. Regulation of nuclear transport: central role in development and transformation?. Traffic 2005, 6:173-186.
25. Zhang Y., Xiong Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 2001, 292:1910-1915.
26. Jain A.K., Jaiswal A.K. Phosphorylation of tyrosine 568 controls nuclear export of Nrf2. J Biol Chem 2006, 281:12132-12142.
27. Turner J.G., Gump J., Ferraro B., Sullivan D. Nuclear and cytoplasmic topoisomerase II alpha are differentially phosphorylated and nuclear export is blocked by CRM1 antisense oligonucleotides. AACR meeting abstracts, vol. 46 2005, 5945.
28. von Knethen A., Tzieply N., Jennewein C., Brune B. Casein-kinase-II-dependent phosphorylation of PPARgamma provokes CRM1-mediated shuttling of PPARgamma from the nucleus to the cytosol. J Cell Sci 2010, 123:192-201.
29. Turner J.G., Dawson J.L., Sullivan D.M. Casein kinase II modulates topoisomerase II alpha nuclear export and drug sensitivity in multiple myeloma. Blood 2012, 120. [abstract].
30. Newlands E.S., Rustin G.J., Brampton M.H. Phase I trial of elactocin. Br J Cancer 1996, 74:648-649.
31. Garzon R.P., Brown D.N., Yee K., Lancet J.E., Gutierrez M., Gabrail N., et al. Phase I trial of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with advanced acute myelogenous leukemia (AML). Blood 2013, 122:1440. [abstract].
32. Gutierrez M., de Nully Brown P., Gabrail N., Baz R., Reece D.E., Savona M., et al. Anti tumor activity of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) XPO1/CRM1 antagonist in patients (pts) with relapsed/refractory multiple myeloma (MM) or Waldenstrom's macroglobulinemia (WM). Blood 2013, 122:1942. [abstract].
33. Gutierrez M., Shah B.D., Gabrail N.Y., de Nully Brown P., Stone R.M., Garzon R., et al. Preliminary evidence of anti tumor activity of selinexor (KPT-330) in a phase I trial of a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Blood 2013, 122:90. [abstract].
34. Mau-Soerensen M., Razak A.R.A., Mahipal A., Mahaseth H., Gerecitano J.F., Shacham S., et al. Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: a phase I study expanded with colon cancer cohort. ASCO meeting abstracts, vol. 32 2014, 482.
35. Razak A.R.A., Soerensen M.M., Mahipal A., Shacham S., Yau C.Y.F., Lassen U.N., et al. First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. ASCO meeting abstracts, vol. 31 2013, 2505.
36. Orlowski R.Z., Nagler A., Sonneveld P., Blade J., Hajek R., Spencer A., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007, 25:3892-3901.
37. Engel R., Valkov N.I., Gump J.L., Hazlehurst L., Dalton W.S., Sullivan D.M. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. Exp Cell Res 2004, 295:421-431.
38. Turner J.G., Marchion D.C., Dawson J.L., Emmons M.F., Hazlehurst L.A., Washausen P., et al. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 2009, 69:6899-6905.
39. Jakob J.A., Bassett R.L., Ng C.S., Curry J.L., Joseph R.W., Alvarado G.C., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118:4014-4023.
40. Pathria G., Wagner C., Wagner S.N. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways. J Invest Dermatol 2012, 132:2780-2790.
41. Salas Fragomeni R.A., Chung H.W., Landesman Y., Senapedis W., Saint-Martin J.R., Tsao H., et al. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther 2013, 12:1171-1179.
42. Faderl S., Talpaz M., Estrov Z., Kantarjian H.M. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999, 131:207-219.
43. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med 1999, 341:164-172.
44. Wang J.Y. Regulation of cell death by the Abl tyrosine kinase. Oncogene 2000, 19:5643-5650.
45. Gong J.G., Costanzo A., Yang H.Q., Melino G., Kaelin W.G., Levrero M., et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999, 399:806-809.
46. Vigneri P., Wang J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001, 7:228-234.
47. Aloisi A., Di Gregorio S., Stagno F., Guglielmo P., Mannino F., Sormani M.P., et al. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood 2006, 107:1591-1598.
48. Walker C.J., Oaks J.J., Santhanam R., Neviani P., Harb J.G., Ferenchak G., et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 2013, 122:3034-3044.
49. Lonial S., Miguel J.F. Induction therapy for newly diagnosed multiple myeloma. J Natl Compr Canc Netw 2013, 11:19-28.
50. Takenaka Y., Fukumori T., Yoshii T., Oka N., Inohara H., Kim H.R., et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004, 24:4395-4406.
51. Newlaczyl A.U., Yu L.G. Galectin-3-a jack-of-all-trades in cancer. Cancer Lett 2011, 313:123-128.
52. Azmi A.S., Kauffman M., McCauley D., Shacham S., Mohammad R.M. Novel small-molecule CRM-1 inhibitor for GI cancer therapy. J Clin Oncol 2012, 30. [abstract].
53. Turner J.G., Dawson J., Sullivan D. KOS-2464, a novel CRM1 inhibitor and a potential drug for multiple myeloma and leukemia. Cancer Res 2012, 72. [abstract].
54. Alexanian R., Delasalle K., Wang M., Thomas S., Weber D. Curability of multiple myeloma. Bone Marrow Res 2012, 2012:916479.
55. Kumar S.K., Lee J.H., Lahuerta J.J., Morgan G., Richardson P.G., Crowley J., et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012, 26:149-157.
56. Zervas K., Mihou D., Katodritou E., Pouli A., Mitsouli C.H., Anagnostopoulos A., et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol 2007, 18:1369-1375.
57. Jakubowiak A.J., Kendall T., Al-Zoubi A., Khaled Y., Mineishi S., Ahmed A., et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009, 27:5015-5022.
58. Valkov N.I., Gump J.L., Engel R., Sullivan D.M. Cell density-dependent VP-16 sensitivity of leukaemic cells is accompanied by the translocation of topoisomerase IIalpha from the nucleus to the cytoplasm. Br J Haematol 2000, 108:331-345.
59. Valkov N.I., Sullivan D.M. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin Hematol 1997, 34:48-62.
60. Dong X., Biswas A., Suel K.E., Jackson L.K., Martinez R., Gu H., et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 2009, 458:1136-1141.
61. Lapalombella R., Sun Q., Williams K., Tangeman L., Jha S., Zhong Y., et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012, 120:4621-4634.
62. Crawford L.J., Walker B., Irvine A.E. Proteasome inhibitors in cancer therapy. J Cell Commun Signal 2011, 5:101-110.
63. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
64. Senda T., Iizuka-Kogo A., Onouchi T., Shimomura A. Adenomatous polyposis coli (APC) plays multiple roles in the intestinal and colorectal epithelia. Med Mol Morphol 2007, 40:68-81.
65. Neufeld K.L., Nix D.A., Bogerd H., Kang Y., Beckerle M.C., Cullen B.R., et al. Adenomatous polyposis coli protein contains two nuclear export signals and shuttles between the nucleus and cytoplasm. Proc Natl Acad Sci U S A 2000, 97:12085-12090.
66. Rosin-Arbesfeld R., Cliffe A., Brabletz T., Bienz M. Nuclear export of the APC tumour suppressor controls beta-catenin function in transcription. EMBO J 2003, 22:1101-1113.
67. Bartholomeusz G., Wu Y., Ali Seyed M., Xia W., Kwong K.Y., Hortobagyi G., et al. Nuclear translocation of the pro-apoptotic Bcl-2 family member Bok induces apoptosis. Mol Carcinogen 2006, 45:73-83.
68. Fabbro M., Henderson B.R. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 2003, 282:59-69.
69. Fabbro M., Rodriguez J.A., Baer R., Henderson B.R. BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export. J Biol Chem 2002, 277:21315-21324.
70. Rodriguez J.A., Henderson B.R. Identification of a functional nuclear export sequence in BRCA1. J Biol Chem 2000, 275:38589-38596.
71. Castoria G., Migliaccio A., Auricchio F. Signaling-dependent nuclear export of estradiol receptor controls cell cycle progression in breast cancer cells. Mol Cell Endocrinol 2009, 308:26-31.
72. Castoria G., Migliaccio A., Giovannelli P., Auricchio F. Cell proliferation regulated by estradiol receptor: therapeutic implications. Steroids 2010, 75:524-527.
73. Nakamura N., Ramaswamy S., Vazquez F., Signoretti S., Loda M., Sellers W.R. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 2000, 20:8969-8982.
74. Haudek K.C., Spronk K.J., Voss P.G., Patterson R.J., Wang J.L., Arnoys E.J. Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta 2010, 1800:181-189.
75. Diehl M.C., Idowu M.O., Kimmelshue K., York T.P., Elmore L.W., Holt S.E. Elevated expression of nuclear Hsp90 in invasive breast tumors. Cancer Biol Ther 2009, 8:1952-1961.
76. Muranen T., Gronholm M., Renkema G.H., Carpen O. Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin. Oncogene 2005, 24:1150-1158.
77. Falini B., Bolli N., Shan J., Martelli M.P., Liso A., Pucciarini A., et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+AML. Blood 2006, 107:4514-4523.
78. Karhemo P.R., Rivinoja A., Lundin J., Hyvonen M., Chernenko A., Lammi J., et al. An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer. Am J Pathol 2011, 179:1004-1014.
79. Khandelwal N., Simpson J., Taylor G., Rafique S., Whitehouse A., Hiscox J., et al. Nucleolar NF-kappaB/RelA mediates apoptosis by causing cytoplasmic relocalization of nucleophosmin. Cell Death Differ 2011, 18:1889-1902.
80. Falini B., Gionfriddo I., Cecchetti F., Ballanti S., Pettirossi V., Martelli M.P. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?. Blood Rev 2011, 25:247-254.
81. Wang W.S., Zhong H.J., Xiao D.W., Huang X., Liao L.D., Xie Z.F., et al. The expression of CFL1 and N-WASP in esophageal squamous cell carcinoma and its correlation with clinicopathological features. Dis Esophagus 2010, 23:512-521.
82. Sanchez A.M., Flamini M.I., Baldacci C., Goglia L., Genazzani A.R., Simoncini T. Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrin 2010, 24:2114-2125.
83. Bourguignon L.Y., Peyrollier K., Gilad E., Brightman A. Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells. J Biol Chem 2007, 282:1265-1280.
84. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001, 3:245-252.
85. Asada M., Yamada T., Ichijo H., Delia D., Miyazono K., Fukumuro K., et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 1999, 18:1223-1234.
86. Hwang C.Y., Kim I.Y., Kwon K.S. Cytoplasmic localization and ubiquitination of p21(Cip1) by reactive oxygen species. Biochem Biophys Res Commun 2007, 358:219-225.
87. Rodriguez-Vilarrupla A., Jaumot M., Abella N., Canela N., Brun S., Diaz C., et al. Binding of calmodulin to the carboxy-terminal region of p21 induces nuclear accumulation via inhibition of protein kinase C-mediated phosphorylation of Ser153. Mol Cell Biol 2005, 25:7364-7374.
88. Keeshan K., Cotter T.G., McKenna S.L. Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway. Br J Haematol 2003, 123:34-44.
89. Susaki E., Nakayama K.I. Multiple mechanisms for p27(Kip1) translocation and degradation. Cell Cycle 2007, 6:3015-3020.
90. Ishida N., Hara T., Kamura T., Yoshida M., Nakayama K., Nakayama K.I. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 2002, 277:14355-14358.
91. Foster J.S., Fernando R.I., Ishida N., Nakayama K.I., Wimalasena J. Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem 2003, 278:41355-41366.
92. Shin I., Rotty J., Wu F.Y., Arteaga C.L. Phosphorylation of p27Kip1 at Thr-157 interferes with its association with importin alpha during G1 and prevents nuclear re-entry. J Biol Chem 2005, 280:6055-6063.
93. Min Y.H., Cheong J.W., Kim J.Y., Eom J.I., Lee S.T., Hahn J.S., et al. Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res 2004, 64:5225-5231.
94. Connor M.K., Kotchetkov R., Cariou S., Resch A., Lupetti R., Beniston R.G., et al. CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell 2003, 14:201-213.
95. Nikolaev A.Y., Li M., Puskas N., Qin J., Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003, 112:29-40.
96. Wadhwa R., Yaguchi T., Hasan M.K., Mitsui Y., Reddel R.R., Kaul S.C. Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res 2002, 274:246-253.
97. Stommel J.M., Marchenko N.D., Jimenez G.S., Moll U.M., Hope T.J., Wahl G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999, 18:1660-1672.
98. O'Brate A., Giannakakou P. The importance of p53 location: nuclear or cytoplasmic zip code?. Drug Resist Update 2003, 6:313-322.
99. Kumari G., Mahalingam S. Extracellular signal-regulated kinase 2 (ERK-2) mediated phosphorylation regulates nucleo-cytoplasmic shuttling and cell growth control of Ras-associated tumor suppressor protein, RASSF2. Exp Cell Res 2009, 315:2775-2790.
100. Knauer S.K., Bier C., Habtemichael N., Stauber R.H. The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO 2006, 7:1259-1265.
101. Knauer S.K., Kramer O.H., Knosel T., Engels K., Rodel F., Kovacs A.F., et al. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 2007, 21:207-216.
102. Maekawa M., Yamamoto T., Nishida E. Regulation of subcellular localization of the antiproliferative protein Tob by its nuclear export signal and bipartite nuclear localization signal sequences. Exp Cell Res 2004, 295:59-65.
103. O'Malley S., Su H., Zhang T., Ng C., Ge H., Tang C.K. TOB suppresses breast cancer tumorigenesis. Int J Cancer 2009, 125:1805-1813.
104. Danks M.K., Garrett K.E., Marion R.C., Whipple D.O. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res 1996, 56:1664-1673.
105. Santos A., Calvet L., Terrier-Lacombe M.J., Larsen A., Benard J., Pondarre C., et al. In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations. Cancer Res 2004, 64:3223-3229.
106. Turner J.G., Sullivan D.M. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 2008, 15:2648-2655.
107. Oloumi A., MacPhail S.H., Johnston P.J., Banath J.P., Olive P.L. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res 2000, 60:5747-5753.
108. Kojima K., Kornblau S.M., Ruvolo V., Dilip A., Duvvuri S., Davis R.E., et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 2013, 121:4166-4174.
109. Shen A., Wang Y., Zhao Y., Zou L., Sun L., Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009, 65. 153-59; discussion 159-60.
110. Zhang K., Wang M., Tamayo A.T., Shacham S., Kauffman M., Lee J., et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 2013, 41:67-78. e64.
111. Schmidt J., Braggio E., Kortuem K.M., Egan J.B., Zhu Y.X., Xin C.S., et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia 2013, 27:2357-2365.
112. Azmi A.S., Al-Katib A., Aboukameel A., McCauley D., Kauffman M., Shacham S., et al. Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. Haematologica 2013, 98:1098-1106.
113. Yao Y., Dong Y., Lin F., Zhao H., Shen Z., Chen P., et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 2009, 21:229-235.
114. Noske A., Weichert W., Niesporek S., Roske A., Buckendahl A.C., Koch I., et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 2008, 112:1733-1743.
115. Azmi A.S., Aboukameel A., Bao B., Sarkar F.H., Philip P.A., Kauffman M., et al. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 2013, 144:447-456.
116. Huang W.Y., Yue L., Qiu W.S., Wang L.W., Zhou X.H., Sun Y.J. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 2009, 32:E315-E321.
117. Yashiroda Y., Yoshida M. Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr Med Chem 2003, 10:741-748.
118. Zaidi S.K., Young D.W., Javed A., Pratap J., Montecino M., van Wijnen A., et al. Nuclear microenvironments in biological control and cancer. Nat Rev Cancer 2007, 7:454-463.
119. Kau T.R., Way J.C., Silver P.A. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004, 4:106-117.